249 related articles for article (PubMed ID: 25314935)
1. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.
Prével C; Kurzawa L; Van TN; Morris MC
Eur J Med Chem; 2014 Dec; 88():74-88. PubMed ID: 25314935
[TBL] [Abstract][Full Text] [Related]
2. Fluorescent biosensors - probing protein kinase function in cancer and drug discovery.
Morris MC
Biochim Biophys Acta; 2013 Jul; 1834(7):1387-95. PubMed ID: 23376184
[TBL] [Abstract][Full Text] [Related]
3. Fluorescent biosensors for high throughput screening of protein kinase inhibitors.
Prével C; Pellerano M; Van TN; Morris MC
Biotechnol J; 2014 Feb; 9(2):253-65. PubMed ID: 24357625
[TBL] [Abstract][Full Text] [Related]
4. Fluorescent protein biosensor for probing CDK/cyclin activity in vitro and in living cells.
Van TN; Pellerano M; Lykaso S; Morris MC
Chembiochem; 2014 Oct; 15(15):2298-305. PubMed ID: 25209885
[TBL] [Abstract][Full Text] [Related]
5. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
6. Fluorescent peptide biosensor for probing the relative abundance of cyclin-dependent kinases in living cells.
Kurzawa L; Pellerano M; Coppolani JB; Morris MC
PLoS One; 2011; 6(10):e26555. PubMed ID: 22028905
[TBL] [Abstract][Full Text] [Related]
7. High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase.
Walker RG; Thomson G; Malone K; Nowicki MW; Brown E; Blake DG; Turner NJ; Walkinshaw MD; Grant KM; Mottram JC
PLoS Negl Trop Dis; 2011 Apr; 5(4):e1033. PubMed ID: 21483720
[TBL] [Abstract][Full Text] [Related]
8. Novel potent pharmacological cyclin-dependent kinase inhibitors.
Węsierska-Gądek J; Chamrád I; Kryštof V
Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
[TBL] [Abstract][Full Text] [Related]
9. Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.
Peyressatre M; Prével C; Pellerano M; Morris MC
Cancers (Basel); 2015 Jan; 7(1):179-237. PubMed ID: 25625291
[TBL] [Abstract][Full Text] [Related]
10. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors.
Cirillo D; Pentimalli F; Giordano A
Curr Med Chem; 2011; 18(19):2854-66. PubMed ID: 21651493
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinases: bridging their structure and function through computations.
De Vivo M; Bottegoni G; Berteotti A; Recanatini M; Gervasio FL; Cavalli A
Future Med Chem; 2011 Sep; 3(12):1551-9. PubMed ID: 21882947
[TBL] [Abstract][Full Text] [Related]
12. Selectivity and potency of cyclin-dependent kinase inhibitors.
Sridhar J; Akula N; Pattabiraman N
AAPS J; 2006 Mar; 8(1):E204-21. PubMed ID: 16584130
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development.
Waters NC; Geyer JA
Expert Opin Ther Targets; 2003 Feb; 7(1):7-17. PubMed ID: 12556199
[TBL] [Abstract][Full Text] [Related]
14. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C
J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794
[TBL] [Abstract][Full Text] [Related]
15. Designing inhibitors of cyclin-dependent kinases.
Hardcastle IR; Golding BT; Griffin RJ
Annu Rev Pharmacol Toxicol; 2002; 42():325-48. PubMed ID: 11807175
[TBL] [Abstract][Full Text] [Related]
16. Fluorescent sensors of protein kinases: from basics to biomedical applications.
Nhu Ngoc Van T; Morris MC
Prog Mol Biol Transl Sci; 2013; 113():217-74. PubMed ID: 23244792
[TBL] [Abstract][Full Text] [Related]
17. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?
Wesierska-Gadek J; Krystof V
Ann N Y Acad Sci; 2009 Aug; 1171():228-41. PubMed ID: 19723060
[TBL] [Abstract][Full Text] [Related]
18. Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
Jorda R; Schütznerová E; Cankař P; Brychtová V; Navrátilová J; Kryštof V
Bioorg Med Chem; 2015 May; 23(9):1975-81. PubMed ID: 25835357
[TBL] [Abstract][Full Text] [Related]
19. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
[TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
